MAPT and amyotrophic lateral sclerosis: In total, the FTD cohort in the present study is composed of 35 individuals: 21 non-genetic probable bvFTD patients, 1 patient with non-genetic bvFTD and ALS, 11 symptomatic C9orf72 mutation carriers, one case of bvFTD due to a GRN mutation (c.328C > T, R110X), and one case with bvFTD due to a MAPT mutation (c.1216C > T, R406W) (Table 1).